Development of an AI-Based Clinical Decision Support Platform

SK bioscience has joined forces with the Bill & Melinda Gates Foundation (the Gates Foundation) to drive innovation in artificial intelligence (AI)-based vaccine research and development.


On July 2, SK bioscience announced that it has been selected as the lead institution for the "ROTOR" project, an AI-based clinical decision support platform development initiative funded by the Gates Foundation. International public health organization PATH and global IT consulting firm Slalom are also participating in this project.


SK Bioscience headquarters in Songdo. SK Bioscience

SK Bioscience headquarters in Songdo. SK Bioscience

View original image

ROTOR is a platform that analyzes immunogenicity and clinical data accumulated during the vaccine development process using AI, supporting research and development decision-making. The goal is to evaluate the probability of candidate success and propose optimal development strategies to enhance the efficiency of vaccine development.


Traditionally, pharmaceutical development determines whether to proceed to Phase 3 clinical trials based on Phase 2 results. However, in the vaccine field, the lack of well-established immunological correlates for predicting preventive effects has often made it difficult to establish development strategies. In particular, Phase 3 clinical trials require large-scale funding and long-term investment, making the establishment of an objective decision-making system a critical issue.


SK bioscience plans to utilize the ROTOR platform to analyze extensive research and clinical data with AI and identify development paths with higher probability of success, thereby reducing uncertainty throughout the vaccine development process. The company also intends to expand the platform's use beyond rotavirus vaccines to various other vaccines and disease areas in the future.


SK bioscience and PATH will build and validate the platform based on their experience and data in rotavirus vaccine development, and aim to help strengthen vaccine development capacity and improve vaccine accessibility in low- and middle-income countries (LMICs).


SK bioscience has recently been strengthening collaborations with global public health organizations. The company signed a license agreement with the U.S. Centers for Disease Control and Prevention (CDC) for the development of an injectable rotavirus vaccine, and earlier this year initiated a partnership with Gates MRI, a research institute under the Gates Foundation, for the development of respiratory syncytial virus (RSV) antibody therapeutics. In February, SK bioscience also secured a project from a European Union (EU) agency to develop a pandemic-response patch-type influenza vaccine.



Jaeyong Ahn, CEO of SK bioscience, said, "This is a new attempt to reduce uncertainty in the vaccine development process and enable scientific decision-making by utilizing AI technology. We will collaborate with global partners to drive innovation in vaccine R&D and improve vaccine accessibility worldwide."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing